This article was downloaded by:


On: 27 January 2011

Access details: Access Details: Free Access

Publisher Taylor & Francis

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-

41 Mortimer Street, London W1T 3JH, UK



### Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information: http://www.informaworld.com/smpp/title~content=t713597286

# Therapeutic Implications of The Unusually Long Half-Life of (E)-5-(2-bromovinyl)uracil (Byura) In Vivo

C. Desgranges<sup>a</sup>; G. Razaka<sup>b</sup>; E. De Clercq<sup>b</sup>; H. Bricaud<sup>b</sup>

<sup>a</sup> Unité 8 de 1'INSERM, Pessac, France <sup>b</sup> Rega Institute, Katholieke Universiteit Leuven, Leuven, Belgium

To cite this Article Desgranges, C. , Razaka, G. , De Clercq, E. and Bricaud, H.(1985) 'Therapeutic Implications of The Unusually Long Half-Life of (E)-5-(2-bromovinyl)uracil (Bvura) In Vivo', Nucleosides, Nucleotides and Nucleic Acids, 4: 1,211-212

To link to this Article: DOI: 10.1080/07328318508077856 URL: http://dx.doi.org/10.1080/07328318508077856

#### PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: http://www.informaworld.com/terms-and-conditions-of-access.pdf

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

## THERAPEUTIC IMPLICATIONS OF THE UNUSUALLY LONG HALF-LIFE OF (E)-5-(2-BROMOVINYL)URACIL (BVUra) IN VIVO

C. Desgranges, G. Razaka, E.De Clercq and H. Bricaud Unité 8 de l'INSERM, Avenue du Haut-Lévêque, 33600 Pessac, France and Rega Institute, Katholieke Universiteit Leuven, B-3000 Leuven, Belgium

Summary - The long half-life of BVUra in the plasma permits, on the one hand, the de novo formation of the antiviral drug (E)-5-(2-bromoviny1)-2'-deoxyuridine (BVdUrd) by a pentosyl transfer, and, on the other hand, the inhibition of the degradation of pyrimidine bases such as 5-fluoro-uracil (FUra).

In contrast to other pyrimidine bases such as uracil (Ura), thymine (Thy), 5-iodoUra, FUra, which are eliminated from the blood stream within 2-4 hours after their administration, BVUra maintains a constant level of 50-70  $\mu$ M in plasma for at least 6 hours. This peculiar behavior is probably due to the lack of degradation of BVUra by the reductive catabolic pathway of pyrimidines.

We have demonstrated that the potent and selective antiherpes agent BVdUrd local could be generated from BVUra in the plasma of rats following the administration of pyrimidine deoxynucleosides such as thymidine, 2'-deoxyuridine (dUrd) or other 5-substituted dUrd derivatives; BVdUrd is formed by a deoxyribosyl transfer from the deoxynucleosides to BVUra catalysed by pyrimidine nucleoside phosphorylases. The generation of the active drug BVdUrd from its inactive metabolite BVUra in vivo can be repeated several times after a single administration of BVUra; and this procedure could be useful to potentiate the clinical efficacy of BVdUrd.

In addition, BVUra is an inhibitor of the reductive step of the pyrimidine catabolism and increases the <u>in vivo</u> half-life of other pyrimidine bases that are normally rapidly degraded, particularly of FUra; and we have demonstrated that the inhibition of FUra degradation is reflected by an increase of the antineoplastic activity of this pyrimidine analogue.

DESGRANGES ET AL. 212

#### REFERENCES

De Clercq, E.; Descamps, J; De Somer, P.; Barr, P.J.; Jones, A.S.; Walker, R.T. Proc. Natl. Acad. Sci. USA 1979, 76, 2947-2951.
Desgranges, C.; Razaka, G.; Bricaud, H.; Herdewijn, P.; De Clercq, E. Nucleic Acids Res. 1984, 12, 2081-2090.